Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 8056 AL 8070

Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders

Sabbagh MN, Cummings JL, Ballard C, van der Flier WM, Heneka MT, Holst JJ, Knudsen LB, Salloway S, Tansey MG, Drucker DJ.

Nat Aging. 2026 Jan;6(1):56-67. doi: 10.1038/s43587-025-01029-3. Epub 2025 Dec 19.

Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial

Kutzsche J, Cosma NC, Kauselmann G, Fenski F, Bieniek C, Bujnicki T, Pils M, Bannach O, Willbold D, Peters O.

Nat Commun. 2025 May 6;16(1):4180. doi: 10.1038/s41467-025-59295-z.

Inhibition of FAM19A5 reverses synaptic loss and cognitive decline in mouse models of Alzheimer's disease

Kim HB, Yoo S, Kwak H, Ma SX, Kim R, Lee M, Ha N, Pyo S, Kwon SG, Cho EH, Lee SM, Jang J, Kim WK, Park HC, Baek M, Park Y, Park JY, Park JW, Hwang SW, Hwang JI, Seong JY.

Alzheimers Res Ther. 2025 Jul 21;17(1):168. doi: 10.1186/s13195-025-01813-8.

Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease

Devanarayan V, Donohue MC, Sperling RA, Johnson KA, Ye Y, Charil A, Doherty T, Tian L, Raman R, Aisen PS, Kramer LD, Irizarry MC, Dhadda S.

Alzheimers Dement. 2025 Sep;21(9):e70702. doi: 10.1002/alz.70702.

Eligibility for donanemab trial in a population-based study of cognitive aging

Jones KE, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR Jr, Vemuri P, Schwarz CG, Lowe VJ, Knopman DS, Petersen RC, Graff-Radford J, Vassilaki M.

J Prev Alzheimers Dis. 2025 Apr;12(4):100088. doi: 10.1016/j.tjpad.2025.100088. Epub 2025 Feb 17.

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease

Rosenberg PB, Amjad H, Burhanullah H, Nowrangi M, Vandrey R, Pierre MJ, Outen JD, Schultz M, Marano C, Agronin M, Wilkins JM, Harper D, Laffaye T, Reardon E, Turner K, Ozonsi R, Drury M, Nguyen A, Hasoğlu T, Cromwell J, Leoutsakos JM, Forester BP.

Am J Geriatr Psychiatry. 2026 Feb;34(2):167-179. doi: 10.1016/j.jagp.2025.10.011. Epub 2025 Nov 10.

Japanese participant data from three gantenerumab trials in early Alzheimer's disease

Asada T, Thanasopoulou A, Delmar P, Wojtowicz J, Smith J, Yoshiyama Y, Yokoi K, Watanabe C, Isozaki M, Ozaki R, Ishida T, Tatsuda H, Tamaoka A.

Alzheimers Dement. 2025 Apr;21(4):e70192. doi: 10.1002/alz.70192.

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study

Pascual-Lucas M, Lacosta AM, Montañés M, Canudas J, Loscos J, Monleón I, Allué JA, Sarasa L, Fandos N, Romero J, Sarasa M, Torres M, Whyms D, Terencio J, Piñol-Ripoll G, Boada M.

Alzheimers Dement. 2025 Oct;21(10):e70776. doi: 10.1002/alz.70776.

The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis

Hsu CW, Hsu TW, Kao YC, Lin YH, Thompson T, Carvalho AF, Stubbs B, Tseng PT, Yang FC, Tsai CK, Yu CL, Tu YK, Liang CS.

J Prev Alzheimers Dis. 2025 Sep;12(8):100195. doi: 10.1016/j.tjpad.2025.100195. Epub 2025 May 1.

Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia

Nakamura Y, Adachi J, Hirota N, Iba K, Sasajima C, Shimizu K, Nakai M, Takahashi K.

Alzheimers Dement. 2025 Jul;21(7):e70522. doi: 10.1002/alz.70522.

Donanemab for Alzheimer's disease: from preclinical research to the clinical application

Dodel R, Frölich L.

Expert Rev Neurother. 2025 Oct;25(10):1151-1163. doi: 10.1080/14737175.2025.2546868. Epub 2025 Aug 25.

Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial

Rajji TK, Baksh SN, Shade DM, Ismail Z, Burhan AM, Okhravi HR, Padala PR, Rosenberg PB, Schneider LS, Porsteinsson AP, Lyketsos CG; S-CitAD Research Group.

Nat Med. 2025 May;31(5):1586-1591. doi: 10.1038/s41591-025-03569-y. Epub 2025 Mar 25.

Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis

Arroyo-Pacheco N, Sarmiento-Blanco S, Vergara-Cadavid G, Castro-Leones M, Contreras-Puentes N.

Ageing Res Rev. 2025 Feb;104:102620. doi: 10.1016/j.arr.2024.102620. Epub 2024 Dec 3.

Implementing early detection of cognitive impairment in primary care to improve care for older adults

Fowler NR, Partrick KA, Taylor J, Hornbecker M, Kelleher K, Boustani M, Cummings JL, MacLeod T, Mielke MM, Brosch JR, Lee J, Shobin E, Galvin JE, Fillit H, Udeh-Momoh C, Willis DR.

J Intern Med. 2025 Jul;298(1):31-45. doi: 10.1111/joim.20098. Epub 2025 May 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias